Why HSBC Just Turned Bearish on Eli Lilly: Price Wars and Overhyped Weight-Loss Expectations

HSBC downgraded Eli Lilly to Reduce from Hold, cutting its price target to $850 from $1,070. The analyst cites an overhyped $150B+ obesity market, rising price competition, and expected cuts in 2026.